A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • 300 Tote jährlich – und der Nachschub an Anti...
Media - published on 21 Jan 2020

300 Tote jährlich – und der Nachschub an Antibiotika stockt

Holger Alich describes the latest findings of the Antimicrobial Resistance Benchmark in Tages-Anzeiger. 

Looking at the impact of antimicrobial resistance in Switzerland, Holger Alich outlines the important role that pharmaceutical companies have in tackling drug resistance. 

Drawing from the results of the 2020 Benchmark, the article highlights that while progress is happening, and some companies are stepping up, others are either maintaining course, or even backing away from the anti-infectives space. The author looks at what this means for the supply on antibiotics in Switzerland. 

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |